KR930019637A - 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 - Google Patents

비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR930019637A
KR930019637A KR1019930003270A KR930003270A KR930019637A KR 930019637 A KR930019637 A KR 930019637A KR 1019930003270 A KR1019930003270 A KR 1019930003270A KR 930003270 A KR930003270 A KR 930003270A KR 930019637 A KR930019637 A KR 930019637A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
hydrogen
formula
general formula
Prior art date
Application number
KR1019930003270A
Other languages
English (en)
Korean (ko)
Inventor
하이트슈 홀거
헨닝 라이너
바그너 아달베르트
게르하르트 헤르만
벡커 라인하르트
쇨켄스 베른바르트
Original Assignee
귀틀라인, 슈미트
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 귀틀라인, 슈미트, 훽스트 아크티엔게젤샤프트 filed Critical 귀틀라인, 슈미트
Publication of KR930019637A publication Critical patent/KR930019637A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019930003270A 1992-03-07 1993-03-05 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 KR930019637A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07
DEP4207241.7 1992-03-07

Publications (1)

Publication Number Publication Date
KR930019637A true KR930019637A (ko) 1993-10-18

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930003270A KR930019637A (ko) 1992-03-07 1993-03-05 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도

Country Status (25)

Country Link
US (1) US5604251A (US20070244113A1-20071018-C00138.png)
EP (1) EP0560177B1 (US20070244113A1-20071018-C00138.png)
JP (1) JP3542813B2 (US20070244113A1-20071018-C00138.png)
KR (1) KR930019637A (US20070244113A1-20071018-C00138.png)
CN (1) CN1036341C (US20070244113A1-20071018-C00138.png)
AT (1) ATE230732T1 (US20070244113A1-20071018-C00138.png)
AU (1) AU663565B2 (US20070244113A1-20071018-C00138.png)
BR (1) BR9300761A (US20070244113A1-20071018-C00138.png)
CA (1) CA2091135A1 (US20070244113A1-20071018-C00138.png)
CZ (1) CZ281983B6 (US20070244113A1-20071018-C00138.png)
DE (1) DE59310323D1 (US20070244113A1-20071018-C00138.png)
DK (1) DK0560177T3 (US20070244113A1-20071018-C00138.png)
ES (1) ES2187501T3 (US20070244113A1-20071018-C00138.png)
FI (1) FI930970A (US20070244113A1-20071018-C00138.png)
HU (1) HUT64041A (US20070244113A1-20071018-C00138.png)
IL (1) IL104971A0 (US20070244113A1-20071018-C00138.png)
MA (1) MA22814A1 (US20070244113A1-20071018-C00138.png)
NO (1) NO303632B1 (US20070244113A1-20071018-C00138.png)
NZ (1) NZ247059A (US20070244113A1-20071018-C00138.png)
PH (1) PH31466A (US20070244113A1-20071018-C00138.png)
PL (1) PL173023B1 (US20070244113A1-20071018-C00138.png)
RU (1) RU2116300C1 (US20070244113A1-20071018-C00138.png)
SK (1) SK279109B6 (US20070244113A1-20071018-C00138.png)
TW (1) TW215434B (US20070244113A1-20071018-C00138.png)
ZA (1) ZA931585B (US20070244113A1-20071018-C00138.png)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CZ263098A3 (cs) 1996-02-20 1999-05-12 Bristol-Myers Squibb Company Způsoby přípravy bifenylisoxazolsulfonamidů
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
CA2274789A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
EP1631268A2 (en) * 2003-05-21 2006-03-08 Board Of Regents The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1685108B1 (en) * 2003-11-03 2008-07-23 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CA2544763A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
EP1699436A2 (en) * 2003-12-12 2006-09-13 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US20060025463A1 (en) * 2004-03-22 2006-02-02 Michael Bristow Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
EP1737447A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US20090220507A1 (en) * 2005-07-22 2009-09-03 Sucharov Carmen C Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
US20090306373A1 (en) * 2005-12-20 2009-12-10 Gamber Gabriel G 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
AU2007281261B2 (en) 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
JP5587777B2 (ja) 2007-07-31 2014-09-10 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 線維症をモジュレートするマイクロrnaファミリー及びその使用
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
EP0599999A1 (en) * 1991-08-19 1994-06-08 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения

Also Published As

Publication number Publication date
IL104971A0 (en) 1993-07-08
ES2187501T3 (es) 2003-06-16
CZ281983B6 (cs) 1997-04-16
ATE230732T1 (de) 2003-01-15
FI930970A0 (fi) 1993-03-04
CA2091135A1 (en) 1993-09-08
FI930970A (fi) 1993-09-08
JPH069572A (ja) 1994-01-18
NO930817L (no) 1993-09-08
NZ247059A (en) 1995-03-28
AU3401193A (en) 1993-09-09
CZ381192A3 (en) 1993-12-15
MA22814A1 (fr) 1993-10-01
PL297955A1 (en) 1993-09-20
EP0560177B1 (de) 2003-01-08
EP0560177A1 (de) 1993-09-15
AU663565B2 (en) 1995-10-12
JP3542813B2 (ja) 2004-07-14
PH31466A (en) 1998-11-03
DE59310323D1 (de) 2003-02-13
RU2116300C1 (ru) 1998-07-27
SK381192A3 (en) 1998-06-03
DK0560177T3 (da) 2003-04-14
PL173023B1 (pl) 1998-01-30
CN1036341C (zh) 1997-11-05
BR9300761A (pt) 1993-09-14
ZA931585B (en) 1993-09-27
US5604251A (en) 1997-02-18
CN1076192A (zh) 1993-09-15
TW215434B (US20070244113A1-20071018-C00138.png) 1993-11-01
HU9300618D0 (en) 1993-05-28
HUT64041A (en) 1993-11-29
NO303632B1 (no) 1998-08-10
SK279109B6 (sk) 1998-06-03
NO930817D0 (no) 1993-03-05

Similar Documents

Publication Publication Date Title
KR930019637A (ko) 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도
RU2337909C2 (ru) Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
ES2173074T3 (es) Derivados de xantina, procedimiento para su preparacion y su uso farmaceutico.
KR890008155A (ko) 신규인 유도체, 그 제조방법 및 의약에서의 사용
MX9200026A (es) Derivados de azol, procedimientos para su preparacion y su utilizacion.
ATE109481T1 (de) Diazinderivate als angiotensin ii rezeptor antagonisten.
ES514267A0 (es) "un procedimiento para la preparacion de derivados de pirrolidina".
KR900006296A (ko) 이미다졸린 유도체 및 그의 제조방법
ATE89547T1 (de) Dopamin-vorlaeufer.
ES2051479T3 (es) Uso de imidazoles substituidos en 4 para disminuir la presion intraocular.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
MA22540A1 (fr) Diaminophtalimides substitues et derives analogues .
KR870007160A (ko) 신규의 디하이드로벤조푸란-및 크로만-카복스아미드 유도체, 그것의 제조 방법 및 신경이완제로서의 사용법
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
IL92799A0 (en) Benzimidazole derivatives with gastric acid inhibition and process for its preparation
DE69330601D1 (de) Serotoninergische ergolin derivate
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법
DE69015787D1 (de) Thiophenderivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DE3568424D1 (en) Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension
KR910021364A (ko) 신규 프로판아민, 그의 약리학적 특성 및 치료 목적, 특히 지사제로서의 용도
MX9206930A (es) Nuevos compuestos
NO950177D0 (no) Farmakologisk aktive erivater
KR880005134A (ko) 인돌로-피라지노-벤조 디아제민 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application